Related Experiment Video
Updated: Jun 1, 2026
11:11
Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
Published on: January 24, 2020
Cytodifferentiation inducers as anticancer agents (review).
1BASIL & GERALD FELSENSTEIN RES CTR,IL-49100 PETAH TIQWA,ISRAEL. TEL AVIV UNIV,ENDOCRINOL LAB,IL-69978 TEL AVIV,ISRAEL. TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL.
Oncology Reports
|May 25, 2011
Summary
This study reviews novel natural and synthetic compounds, including protein kinase analogues and vitamin D-3, showing promise as anticancer agents in differentiation therapy for leukemic diseases.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Differentiation therapy has shown success in treating leukemic diseases.
- There is renewed interest in developing effective differentiation agents.
Purpose of the Study:
- To review novel natural and synthetic compounds with anticancer potential.
- To focus on agents not extensively covered in previous literature.
Main Methods:
- Literature review of biological activities.
- Summary of preclinical studies.
- Overview of clinical investigations.
Main Results:
- Identified promising novel compounds: protein kinase analogues, butyric acid, vitamin D-3, and purine/pyrimidine derivatives.
- Detailed biological activities and therapeutic potential of these agents.
- Compiled preclinical and clinical data supporting their efficacy.
Conclusions:
- Novel compounds show significant promise as anticancer agents in differentiation therapy.
- Further research and clinical trials are warranted for these agents.
- These agents represent a valuable addition to the therapeutic arsenal against leukemic diseases.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...